Skip to main content
AJOG Global Reports logoLink to AJOG Global Reports
. 2025 Aug 22;5(4):100563. doi: 10.1016/j.xagr.2025.100563

Sacral Tarlov cysts and spontaneous persistent genital arousal: 2 unrecognized and underappreciated health conditions with an uncertain relationship

Randa Yosef a, Gaylene Pron b,⁎, Nucelio Lemos c, Kieran Murphy d
PMCID: PMC12861627  PMID: 41631178

Abstract

Tarlov cysts commonly occur in women but are often thought to be asymptomatic findings. However, recent studies have suggested that Tarlov cysts can be a contributing factor to various pain and neurologic dysfunctions with a significant effect on health-related quality of life. Tarlov cysts and various intrapelvic pathologies can result in compression or impairment of peripheral and spinal nerve roots and can potentially affect women’s sexual function, particularly by causing persistent genital arousal disorder. Persistent genital arousal disorder is characterized by spontaneous and often unrelenting sensations of genital arousal in the absence of sexual desire or stimulation and, by definition, is intrusive, unwanted, and distressing. This review details the prevalence, characteristics, and treatments of persistent genital arousal disorder and Tarlov cysts and evaluates potential relationships between these conditions.

The prevalence of persistent genital arousal disorder ranges from 1.6% to 11.1% in community-based surveys, and 33% of women who are referred to a sexual health clinic report at least 1 persistent genital arousal disorder screening question. The prevalence of Tarlov cysts ranges from 1.5% to 13.2% and is higher among women referred to pain centers, ranging from 16% to 39%. Despite the already high prevalence, these numbers for both conditions are likely underestimated as sexual dysfunction. Therefore, persistent genital arousal disorder is not readily disclosed, and optimal sacral magnetic resonance imaging is infrequently performed to detect Tarlov cysts. Persistent genital arousal disorder is a symptom complex for which psychological, vascular, central, and peripheral neurologic factors have been proposed as possible causes.

When peripheral nerve entrapments are believed to be the cause of persistent genital arousal disorder, mechanical release of the nerve or nerve root is the generally accepted treatment. Several surgical and minimally invasive percutaneous procedures are effective treatments when Tarlov cysts are symptomatic, although evidence for their effectiveness for persistent genital arousal disorder is limited. For surgical/interventional failures to decompress nerves and decrease symptoms in patients with Tarlov cysts or persistent genital arousal disorder, neuromodulation is increasingly being performed as a rescue therapy.

Because of the weak evidence base, the relationship between Tarlov cysts and persistent genital arousal disorder remains uncertain, and healthcare professionals are encouraged to inquire more broadly about the symptoms related to these conditions, conduct neurologic examinations, and order relevant sacral imaging to clarify the relationship further.

Key words: overactive bladder, pelvic pain, pelvic varices, pudendal nerve, restless leg syndrome, sacrum, sexual dysfunction, spontaneous genital arousal, Tarlov cyst, women’s health


AJOG Global Reports at a Glance.

Why was this study conducted?

This review details the prevalence, characteristics, and treatments of 2 relatively unknown conditions, namely, spontaneous persistent genital arousal disorder (PGAD) and Tarlov cysts, a potential trigger for PGAD. Increased awareness of these conditions and knowledge of appropriate diagnostics and treatments may improve gynecologic care for patients with these conditions, who often go undiagnosed and unmanaged, resulting in months, if not years, of distress and disability.

Key findings

Recent community- and clinic-based surveys suggest that PGAD occurs more frequently than previously thought. Although the prevalence of Tarlov cysts is also likely underestimated, often due to limited lumbosacral magnetic resonance imaging, higher prevalence has been reported in studies targeting women referred for gynecologic or urologic conditions. Both PGAD and Tarlov cysts can be associated with various genital pain and urologic and neurologic disorders. For patients with urinary complaints or genital pain/dysesthesias, discussing sexual function is crucial because of the shared neural pathways for bladder and sexual functions. When peripheral or spinal nerve compressions caused by Tarlov cysts or other endopelvic conditions are believed to be the cause of PGAD, surgical/interventional procedures to release nerve compression are accepted treatments. For failures to decompress nerves and decrease symptoms in patients with Tarlov cysts or PGAD, neuromodulation is increasingly being performed as a rescue therapy.

What does this add to what is known?

This review highlights the recognition, importance, and treatments of PGAD, a spontaneous, unwanted, and distressing condition. In addition, practical suggestions were made on guidance to clinicians on how to determine whether Tarlov cysts are the cause of PGAD in their clinical practice. Given the complex interplay between neurologic, gynecologic, and urologic factors in PGAD and Tarlov cysts, increased understanding and standardized protocols for evaluating sacral and intrapelvic pathology in patients could improve diagnosis and guide more effective treatment strategies.

Introduction

Tarlov cysts are cerebrospinal fluid (CSF)-filled sacs from the spinal nerve root sheath that commonly develop along the sacral spine. Historically, these cysts have been described as an incidental finding on magnetic resonance imaging (MRI) with little clinical relevance.1, 2, 3 Tarlov cysts commonly exist in women but are often overlooked as a cause of various pain, neurologic disorders, and dysfunctions. However, recent studies suggest that Tarlov cysts can be a contributing factor to such conditions.4, 5, 6

Persistent genital arousal disorder (PGAD) is a condition of spontaneous, unrelenting sensations of genital arousal in the absence of sexual desire or stimulation and, by definition, is intrusive, unwanted, and distressing.7 In addition, the sensations were noted to typically be unresolved with an ordinary orgasmic experience and could be accompanied by uncontrollable orgasms and/or having an excessive number of orgasms. Moreover, the condition may include lower extremity genital paresthesia or dysesthesia (GPD) because of the involvement of common sacral nerve roots.8 Both conditions affect the quality of life of patients who experience them.

There has been uncertainty over the etiology of PGAD. However, PGAD has been increasingly thought to be a symptom resulting from different possible underlying causes.9,10 In some cases, medical management, particularly for depression, has been reported to trigger PGAD, particularly selective serotonin reuptake inhibitors (SSRIs).11 In addition, there have been some suggestions that vascular disruptions with pelvic varices occur commonly with PGAD.12 Moreover, neurologic damage or abnormalities attributable to intrapelvic nerve entrapment, small fiber neuropathy, or compression in the spine involving Tarlov cysts or intervertebral disk pathology have been implicated, especially when PGAD is associated with genital, gluteal, and/or lower extremity dysesthesia or paresthesia.7,8,13, 14, 15

The International Society for the Study of Women’s Sexual Health (ISSWSH) 2021 PGAD consensus outlined a range of potential psychosocial and comorbid factors organized over 5 regions contributing to PGAD—the end organ, pelvis/perineum, cauda equina, spinal cord, and brain.8 The focus of this report is on Tarlov cysts, which have a potential role in PGAD related to their location in the sacral spinal region, particularly when located at the S2 to S3 level, which originate from fibers forming the pudendal and pelvic splanchnic nerves innervating the genitopelvic region. These nerves have important sensory and motor functions that innervate the perineum, external genitalia, and pelvic floor muscles. Thus, cysts, depending on their size and location, compressing or irritating the nerve roots can contribute to various dysesthesias and pain in these regions.8

The objectives of this narrative review are to detail the prevalence, characteristics, and treatments of PGAD and Tarlov cysts, evaluate their potential relationships, and provide some guidance to clinicians on how to determine whether a Tarlov cyst is the cause of PGAD in their clinical practice. Peer-reviewed studies evaluating these topics without date restrictions were included in the review.

Prevalence of persistent genital arousal disorder

PGAD was first described in 2001 by Leiblum and Nathan16 based on a clinical series of 5 women presenting with physiological signs of PGAD, unrelated to sexual excitement or desire, involving distressing and worrisome feelings. Since then, the condition has been reported in several community-based surveys, and although there has been no consensus on the diagnosis of PGAD, several diagnostic criteria have been commonly employed in studies, including the following16:

  • •

    The genitals are persistently aroused.

  • •

    Arousal remains after orgasm or requires multiple orgasms to diminish.

  • •

    Arousal is unrelated to desire.

  • •

    Arousal is triggered by nonsexual stimuli.

  • •

    Symptoms are intrusive and unwelcomed.

Of note, 2 community-based surveys assessed the prevalence of PGAD among Internet-recruited subjects. Moreover, 1 survey17 involved Canadian undergraduate students (n=1627) and a nationally representative sample (n=1020) from the United States. In the Canadian sample, 0.6% of female students and 1.1% of male students reported symptoms of PGAD, and in the companion American survey, 2.7% of women and 4.3% of men reported symptoms of PGAD. Although there was a higher prevalence of PGAD endorsements among Americans, the mean age was higher—46.1 years in the American group vs 18.2 years in the Canadian group. In a survey18 of Italian university female students (n=679), PGAD endorsements were higher than those by Canadian female students (1.6% vs 1.1%, respectively), and endorsements of each PGAD diagnostic criterion and negative emotions expressed with their symptoms were also higher (Supplemental Table 1).

Characteristics of persistent genital arousal disorder

Although PGAD is primarily classified as a neurologic and sexual disorder, many of its symptoms overlap with conditions commonly encountered in gynecology, urology, and pelvic pain clinics. As PGAD often remains undiagnosed in gynecologic settings, it is crucial for gynecologists to recognize its symptoms and potential links with sacral pathology (such as Tarlov cysts), which can improve diagnostic accuracy and guide referrals to neurology or pain specialists.

Of note, 3 online surveys were conducted,19, 20, 21 recruiting women experiencing PGAD symptoms (Supplemental Table 2). In Jackowich et al’s19 survey (n=115), 47.8% of respondents reported all 5 PGAD diagnostic criteria, and 34.0% of respondents reported fewer diagnostic criteria. A range of medical symptoms were reported, and almost all participants reported that arousal, urinary, and pain symptoms were highly distressful, unwanted, and associated with negative feelings. In Leiblum et al’s20 first survey (n=103), 53% of respondents reported all 5 PGAD diagnostic criteria with a mean symptom duration of 7.0 years, resulting in high symptom intensity and distress related to intrusiveness, continuity, and shame. In their second larger survey (n=388), respondents reporting all 5 PGAD diagnostic criteria were more likely than those reporting fewer criteria to report that PGAD symptoms were continuous (47.6% vs 27.1%, respectively) and that the strength of symptoms was overwhelming (32.3% vs 13.6%, respectively).21

Other online studies have made comparisons between different PGAD groups22 and between PGAD and control groups.23,24 Jackowich et al22 compared the characteristic of 3 groups of women—women reporting persistent genital arousal (PGA) symptoms (n=42), women having painful symptoms of PGA (n=37), and women having chronic vulvar pain (CVP) (n=42). The medical comorbidities and endorsements of PGA symptoms were significantly different between the groups (Supplemental Table 3). The McGill pain score ratings did not differ between the groups, although the sensory subscale (pain intensity) was rated higher in the painful PGA and CVP groups, and the affective subscale (unpleasantness of pain symptoms) was rated higher in the PGA group. Pain catastrophizing scores, particularly the helplessness subdomain, were significantly higher in the PGA groups, likely related to the spontaneous and uncontrollable nature of PGAD. Although all participants reported that their symptoms adversely affected their psychological function and social activity, the PGA groups reported significantly more interference in work performance.

Of note, 2 Internet-based surveys in different countries compared women with PGA with age-matched controls (Supplemental Table 3). Jackowich et al23 compared a Canadian/American cohort of women experiencing symptoms of PGA (n=72) with a control group (n=72), and Kümpers et al24 compared German women more formally diagnosed with PGAD (n=26), who were younger than those in the Jackowich et al23 study (39.5 vs 45.4 years, respectively), with controls (n=26).

Jackowich et al23 found significantly more medical, pelvic/urogenital, and pain-related conditions in the PGA group than in the control group. In both surveys, restless leg syndrome and urinary dysfunctions were significantly more common in the PGA groups. Depression and anxiety, measured using the Beck Depression Inventory in Jackowich et al’s23 study and the Hospital Anxiety and Depression Scale in Kümpers et al’s24 study, were significantly higher in women with PGA. Although group differences in suicidality were not detected in Kümpers et al’s study,24 more than twice as many women in the PGA group than in the control group (54.2% vs 25.0%) expressed some degree of suicide ideation in Jackowich et al’s23 study. Personality or developmental disorders, extensively evaluated by Kümpers et al,24 were not significantly different between the study groups.

Sexual function assessed using the Female Sexual Function Index in Jackowich et al’s23 study found that women with PGA reported significantly more sexual distress and less relationship satisfaction. However, many women did not complete the questionnaire, and in open-format questioning, the women reported that PGA had affected their sex life, making them fearful of triggering symptoms and avoiding sex to limit flares. Kümpers et al24 assessed sexual function using the International Classification of Diseases, 10th Revision, and found that women with PGAD were also diagnosed significantly more often than controls (21 vs 1, respectively) with sexual dysfunctions. Quality of life and sleep quality, which were assessed for the first time by Kümpers et al,24 were both significantly poorer in the PGAD group. In imaging investigations, pelvic varices (2 [PGA group] vs 0 [control group]) and Tarlov cysts (13 [PGA group] vs 9 [control group]) occurred more often in women with PGA than in controls, although the differences were not significant. In peripheral electroneurographic studies, only the prolonged latency in the sensory-evoked potential of the pudendal nerve was significantly different between the groups.

As PGAD was first described in a small case series,16 characteristics of women with PGAD have been described in several clinical studies, although none have involved control or comparative groups (Table 1).12,25, 26, 27 Among women attending a walk-in sexual health clinic in the United Kingdom, 32 of 96 women (33%) reported at least 1 PGAD screening question.25 The 1 woman (1.0%) reporting 5 PGAD criteria had symptoms for several years and had not previously disclosed them.

Table 1.

Clinical studies evaluating patients with persistent genital arousal disorder

Author, report year, and study objective Study setting, sample, methods Main findings
Garvey et al,25 2009
United Kingdom
• To evaluate the frequency and nature of spontaneous GA and PGAD in women attending a walk-in sexual health clinic in London
• 153 women attended a walk-in sexual health clinic in London, of whom 96 (63%) agreed to participate in the study and completed an anonymous questionnaire
• 2-stage screen and diagnosis with screening, including responses to 3 GA-related questions experiencing (1) sexual arousal not related to sexual excitement or desire, (2) signs of genital arousal that persisted for an extended period and does not subside spontaneously, and (3) arousal that does not resolve with an ordinary orgasm and may take more than 1 orgasm over hours or days to remit
• Individuals responding positively to any of the screening questions were asked 3 diagnostic questions: (1) feeling persistent arousal distressing on a scale 1 to 10, (2) duration of symptoms of persistent genital arousal, (3) intensity of feeling on a 5-point scale, and (4) feelings of arousal are intrusive or unwanted
• The median age was 28 y (IQR, 18–64), sexual orientation was heterosexual (95%), 45% of individuals were single, and 49% of individuals had a regular partner
• At least 1 GA screening question was endorsed by 33 individuals (33%), 19 individuals (20%) reported absence of desire, and 3 individuals (3%) reported absence of desire over an extended period
• 1 woman (1%) aged 38 y, heterosexual and single, responded positively to all diagnostic PGAD criteria, with symptoms that were distressful and occurring for many years and had not been previously disclosed
• 2 women (2%) aged 20 and 32 y, both heterosexual and single, responded to 4 of the 5 PGAD diagnostic criteria, with symptoms mildly distressing and involving mixed positive and negative emotions
• Of 2 women, 1 had hypertension, endometriosis, mild asthma, history of depression, anxiety, eating disorder, and past overdose, and the other had no medical or gynecologic history
• 3 women experienced PGAD symptoms, but sensations were not intrusive or distressing
Pink et al,26 2014
Canada
• To better understand the PGAD disorder in women and review similarities among cases of PGAD encountered in a chronic noncancer pain management clinic
• 15 women referred with chronic pain and diagnosed with PGAD were interviewed to examine history and findings
• The mean age of women was 37.9±14.6 y, all individuals were heterosexual, and 60% of individuals were in relationships
• Information on demographics, medical history, sexual functioning, medication history, description of symptoms, alleviation and symptom duration
• Physical examinations included genital inspection, sensation testing, Q-tip testing, and digital genital examination
• Laboratory and imaging investigations were variably performed: pelvic ultrasound (40.0%), pelvic MR venography (40.0%), and brain MRI (33.3%); frequency of other investigations were not reported, including spine and abdomen MRI scans, CT scans, PET scans, pelvic X-ray, and electromyography
• The mean age of PGAD onset was 25.6±16.2 y
• Depression and anxiety were reported by 9 (60%) and 6 (40%) individuals, respectively
• All women reported being disabled by PGAD, and for most respondents, daily activities were curtailed
• Most individuals reported no precipitating event for PGAD; 3 women reported occurrence after surgical injuries
• Multiple common comorbidities were reported, including various pain conditions currently treated with benzodiazepines (n=5) or short-acting (n=4) or long-acting (n=5) opioids
• Pain conditions included pelvic and/or genital pain (n=9), clitoral pain (n=3), neuropathic pain (n=3), fibromyalgia (n=3), irritable bowel syndrome (n=3), facial pain (n=2), pudendal neuralgia (n= 6), restless leg syndrome (n=5), and other medical conditions, including bladder symptoms (n=8), sleep apnea (n=3), GI reflux (n=2), PID (n=2), and Ehlers-Danlos syndrome (n=1)
• Physical examination was significant in 12 women (80%): positive Q-tip (n=9), pain on digital examination or palpation (n=4), pain on clitoral examination (n=3), hyperalgesia (n=1), and hypoesthesia (n=1)
• Imaging investigations reported 3 findings: Tarlov cyst (n=1), adenomyosis (n=1), and nonspecific foci on brain MRI (n=1)
Oaklander et al,27 2020
United States
• To conduct interviews and neurologic examinations in patients identified with PGAD through record reviews of a university hospital neurology practice
• In 10 women with PGAD, most were self-diagnosed on line (n=8) and had sought care for other medical conditions and only reported PGAD after trust
• The mean age was 53.4 y (range, 29.3–79.8)
• Information was collected on demographics, medical history, lumbosacral and MRI scans
• Neurologic examinations were conducted, and results on symptom localization, etiology, and treatment were determined
• PGAD onset ranged from puberty to postmenopausal and arousal occurring episodically and sustained—daily transient arousals (n=8 [80%]) and lesser near continuous arousals for days and years (n=4 [40%]); 2 women had both patterns
• Chronic PGAD always terminated sexual relations
• PGAD caused new or worsening depression and anxiety in all women
• Bladder dysfunction—frequency, urgency, incontinence, or bladder pain was reported by 7 individuals (70%)
• Neurologic symptoms occurred in 7 individuals (70%) in the perineum, back, buttocks, hands, and feet and included numbness, itching, paresthesia, sensory loss, and restless leg
• MRIs of the brain were noncontributory, and 6 of 8 MRIs associated with sacral radiculopathy were associated with Tarlov cysts in 5 cases
• Nerve conduction tests were diagnostic for sensory polyneuropathy in 2 of 2 tests performed, and peripheral nerve testing with immunolabeled leg skin biopsies was abnormal in 2 of 5 cases
• Treatments of PGAD were ineffective or providing only temporary relief; among them, electroconvulsive therapy, gynecologic and urologic medications, transcutaneous electrical nerve stimulation, local anesthetics and/or corticosteroid administrations, genitofemoral nerve blocks, and pudendal nerve blocks
• Presumed PGAD causation: Tarlov cysts (n=5), herniated spinal disk (n=1), spina bifida occulta (n=1), small fiber neuropathy (n=1), sudden duloxetine discontinuation (n=1), and unknown with sacral MRI recommended (n=1)
Waldinger et al,12 2009
The Netherlands
• To investigate possible causes of PGAD in women presenting at an outpatient department of neurosexology
• 18 women seeking medical care for complaints of unwanted genital arousal sensations and diagnosed with PGAD
• The mean age was 53.7±9.7 y (range, 30–70), satisfying all 5 PGAD diagnostic criteria
• The mean age at onset of PGAD was 49.5±11.8 y (range, 20–68)
• 15 individuals (83%) were in relationships with male partners for a mean duration of 24.7 y
• 12 individuals (67%) were menopausal, and all individuals were in good physical health
• Investigations in all women included routine blood and hormonal tests, EEG, and MRI of the brain and pelvis; TVUS and contrast MRI were performed in those with MRI abnormalities
• All women reported social withdrawal and feelings of dysthymia, agitation, or depressed mood related to the persistent unwanted genital sensations
• Symptoms were experienced continuously through the day by all women, varying from severe to very severe sensations
• Unwanted genital sensation were felt in variable regions: clitoris (n=14), vagina (n=10), labia (n=5), behind the pubic bone (n=1), and in the groin (n=2)
• Genital sensations were followed by feeling of imminent orgasm that did not complete in 15 individuals (83%)
• Routine blood analyses, iron analyses, and endocrine assessments were all within normal ranges
• EEG studies revealed no severe diffuse or focal abnormalities of the brain
• MRI brain scans were normal, except for pericallosal aneurysm (n=1) and postoperative changes after meningioma removal surgery (n=1)
• Pelvic MRI scans indicated ovarian cysts (n=3) and uterine fibroids (n=2)
• TVUS, performed in the 12 women whose pelvic MRI showed pelvic varices (n=10) or cysts (n=2); confirmed pelvic varices (n=9) with mild (n=2), moderate (n=3), or severe (n= 4) occurrences
• Additional MRI with gadolinium for individuals with severe pelvic varices revealed mild to moderate dilation of ovarian veins (n=3)
• Varices in 1 leg or both legs were reported by 7 individuals (39%), 5 of whom underwent varices surgery
Waldinger et al,28 2009
The Netherlands
• To investigate features, possible causes, and treatment of PGAD in women presenting to an outpatient department of neurosexology
• The same cohort of 18 women with PGAD as in Waldinger et al12 • Previous treatments for 7 individuals (39%) were unsuccessful: psychotherapy, pelvic floor exercises, and drug therapies
• Overactive bladder, urinary urgency, and voiding frequency were reported by 12 individuals (67%)
• Restless leg syndrome was reported by 12 individuals (67%) in different degrees and frequencies; 6 women reported symptoms for many years; no abnormalities were noted in iron metabolism
• Genital dysesthesias and paresthesias were expressed with similar neuropathic pain terms as those of restless leg syndromes–tingling, creeping sensations, burning feelings, painful spasms, and electric currentlike or little explosive sensations
• Clonazepam was used by 16 individuals (89%) and had variable effects on PGAD, ameliorating effects only in the short term (n=4) and variably decreased symptoms by 50% to 90% in others
Villot et al,29 2016
France
• To conduct interviews, medical, and neurologic examinations and evaluate the role of the pudendal nerve by EMG testing in women with PGAD
• 23 women diagnosed with PGAD were referred by gynecologists or general practitioner to the department of meurology for perineal EMG evaluation of PGAD symptoms
• The median age was 55.5 y (IQR, 38.7–63.5), 60.8% of individuals were menopausal, and all individuals were in good physical health except for genital complaints
• The median time to seeking treatment was 12.0 mo (IQR, 10.5–24.0)
• Investigations included full neurologic examinations, perineal examinations, brain and spinal cord MRIs, and EMG perineum study
• In cases of abnormal gynecologic findings, a pelvic MRI or ultrasound was performed
• Perineal pain in 16 individuals (70%) and perineal dysesthesia in 8 individuals (35%)
• PGAD sensations experienced on the vagina (n=20), clitoris (n=16), and labia (n=13)
• 3 patients treated for depression, all with SSRI antidepressants
• Overactive bladder and restless leg syndrome in 7 (30%) and 2 (9.0%) individuals, respectively
• Abnormal EMGs in 14 individuals (61%), of which bilateral denervation of the anal sphincter muscle or the sphincter anal muscle occurred in 11 individuals
• Individuals with abnormal EMG (n=14) experienced the following: sacral reflex latencies delayed in 6 individuals (43%), delayed latency of the anal branch of the pudendal nerve and elongated latency of the perineal branch of the pudendal nerve in 9 individuals (64%), and delayed pudendal nerve terminal motor latency of both the anal branch and perineal branch in 10 individuals (71%)

CT, computed tomography; EEG, electroencephalographic; EMG, electromyography; GA, genital arousal; GI, gastrointestinal; IQR, interquartile range; MR, magnetic resonance; MRI, magnetic resonance imaging; PET, positron imaging tomography; PGAD, persistent genital arousal disorder; PID, pelvic inflammatory disease; SSRI, selective serotonin reuptake inhibitor; TVUS, transvaginal ultrasound.

Yosef. Tarlov cysts can potentially cause persistent genital arousal disorder. Am J Obstet Gynecol Glob Rep 2025.

Other women with PGAD (n=15) presenting at a chronic noncancer pain clinic in Canada reported various pain-related conditions and were treated mainly with benzodiazepines and short- or long-acting opioids.26 Depression, which was reported by 60% of women, was commonly treated with tricyclic antidepressants. Imaging investigations were not regularly scheduled, and findings were limited: a Tarlov cyst in 1 case and adenomyosis in another case.

Many associated symptoms support the hypothesis of sacral nerve root or peripheral nerve entrapments as a cause of PGAD. Women with PGAD (n=10) presenting at a neurology practice in the United States commonly reported urinary dysfunctions.27 PGAD caused or worsened symptoms, and symptom onset resulted in confusion, shame, and fear. Neurologic testing revealed radiculopathy (n=6), and nerve conduction tests were diagnostic for sensory polyneuropathy (n=2). Various spinal pathologies, including Tarlov cysts (n=5), herniated discs (n=2), facet arthropathy (n=2), and foraminal erosion/stenosis (n=3), were reported.

For women (n=18) presenting to an outpatient neurosexology department in the Netherlands, routine blood analyses were normal, and abnormalities were not reported in electroencephalographic studies or MRI brain scans.12 Pelvic MRI indicated pelvic varices in 10 women. In their second report,28 restless leg syndrome was reported by 12 women, of whom 7 reported that symptoms occurred shortly after PGAD diagnosis. Almost all were treated with clonazepam, with variable effects on PGAD symptoms. In addition, overactive bladder syndrome was reported by 12 women, as urinary frequency is a side effect of clonazepam, which may have been a contributing factor. The descriptions of genital symptoms of dysesthesias/paresthesias were similar to the terms used to describe restless leg syndrome: “tingling, ants walking, cramps, creeping, burning feelings, painful spasms, and electric currentlike sensations.”

Women with PGAD (n=23) referred to a neurology department underwent a complete series of investigations—full neurologic examinations, brain and spinal MRIs, perineal examination, and perineal electoneuromyography.29 Of note, 3 findings of MRI that identified brain and spinal abnormalities were reported, but the nature of the anomalies was not identified. Overactive bladder and restless leg syndrome were reported in 7 (30.4%) and 2 (8.7%) patients, respectively. Most patients had neuropathic changes (61%), and those with abnormal electromyography (EMG) findings (n=14) had multifocal damage to the perineal nerve, proximally and distally. The abnormal EMG findings included denervation of the anal sphincter muscle (n=14) and delayed sacral reflex latencies (n=6). Abnormalities of the pudendal nerve included delayed latency of the anal branch (n=9) and elongated latency of the perineal branch (n=9).

Tarlov cysts

Perineural cysts first characterized in1938 by Isadore Tarlov30 were initially seen as anatomic variants of uncertain clinical significance. Tarlov cysts are CSF-filled sacs commonly occurring at the junction of the posterior root and the dorsal ganglion.31 Nerve root fibers and occasionally ganglion cells exist within the cyst wall or freely in the cyst, and the entire cyst may be surrounded by neural tissues.32,33 Although the pathogenesis of Tarlov cysts is unclear, the currently accepted cause of cyst development is a disruption of the CSF-venous drainage mechanism at the perineurial-epineurium junction.32, 33, 34 Cyst enlargement is thought to occur because microcommunication exists between the cyst and the subarachnoid space, and a ball-valve type mechanism allows CSF influx and restricts efflux, leading to an expansion of the cyst (Figure).31,35, 36, 37 A potential association of inherited connective tissue disorder syndromes, such as Marfan syndrome and Ehlers-Danlos syndrome, with Tarlov cysts has been suggested, as these syndromes commonly have dural ectasia (widening of the dural sac) thought to be a precursor to the development of Tarlov cysts.38,39 However, the prevalence of Tarlov cysts in these syndromes is unknown, reported only in case reports.40,41

Figure.

Figure

Axial and sagittal imaging of the Tarlov cyst

Axial (A) and sagittal (B) T2 magnetic resonance imagings show Tarlov cyst (arrow) within the sacral canal at the S1 level.

Yosef. Tarlov cysts can potentially cause persistent genital arousal disorder. Am J Obstet Gynecol Glob Rep 2025.

Prevalence of Tarlov cysts

In different studies on patients referred for low back pain, sciatica, or other spinal pathology, the prevalence of Tarlov cysts ranged from 1.5% to 13.2%.31,42, 43, 44, 45, 46, 47, 48, 49 The highest prevalence was found for studies employing sacral MRIs.42,45,49 Klepinowski et al’s50 meta-analysis of 22 imaging studies reported a prevalence rate of 4.18% (95% confidence interval, 2.47%–6.30%) for Tarlov cysts. However, Tarlov cysts have been generally underestimated in these studies as other spinal causes of pain and neurologic dysfunctions were mainly investigated.46

In studies targeting women referred for gynecologic or urologic conditions,51, 52, 53 the prevalence of Tarlov cysts was reported to be higher. In a cohort of 197 patients (180 women and 17 men) referred to an outpatient musculoskeletal pain clinic diagnosed with fibromyalgia or chronic fatigue syndrome, Tarlov cysts were seen on lumbosacral MRIs in 39% of patients (75 women and 2 men).51 In an American cohort of 242 patients presenting to an academic chronic pain center with pudendal neuralgia and chronic pelvic pain, 16% of patients (34 women and 5 men) had at least 1 Tarlov cyst.52 In a Japanese cohort of 102 women who underwent pelvic MRI and subsequently sacral MRI, Tarlov cysts were diagnosed in 6.9% of patients.53

Characteristics of Tarlov cysts

Tarlov cysts have commonly been reported to be associated with isolated lower limb radiculopathy and paresthesias, but their correlation with genital pain, urinary, and sexual dysfunction has been much less studied.54,55 In an early report46 of Australian patients with sacral Tarlov cysts referred for a surgical opinion, MRI studies were conducted to clarify the relationship between Tarlov cysts and typical symptoms of spinal stenosis. Consequently, focus on these symptoms and lack of gynecologic or urologic investigations are reasons why the broader clinical effects of sacral Tarlov cysts have been overlooked.2 Inquiry into other symptoms, particularly sexual function, is rare as many spine surgeons focus on the disk space and are uncomfortable discussing genital pain and sexual dysfunction.56 Dutch neurosurgeons reported that they felt that sexual health was affected in 34% of their patients and that responsibility was with the neurosurgeon (partly) to investigate. However, 73% of neurosurgeons reported that they almost never do this.57

Tarlov cysts were investigated more extensively in multidisciplinary investigations,4, 5, 6,46,52,58 and pain symptoms in diverse regions and bowel and bladder dysfunctions were commonly reported (Supplemental Table 4). Of note, 1 study5 comparing patients with Tarlov cysts with age-matched controls reported higher frequencies for conditions in the lower limbs (pain/paresthesia in the feet and leg weakness) and pelvis (perineal pain/paresthesia or coccygodynia). Although sexual dysfunction was not reported, perineal paresthesia (24% [patients with Tarlov cysts] vs 5% [controls]) and dyspareunia (32% [patients with Tarlov cysts] vs 5% [controls]) were more commonly reported by patients with Tarlov cysts than by controls. Sexual dysfunctions, although without specific symptoms, were reported in other studies involving Tarlov cysts, with prevalence ranging from 25.0% in a cohort of 65 patients,4 29.3% in a cohort of 157 patients,58 and 43.0% in a cohort of 213 patients.6 Of note, 1 study52 involving a cohort of 242 patients with pudendal neuralgia identified 34 patients (34 women and 5 men) with at least 1 sacral Tarlov cyst. Of the women with Tarlov cysts, 2 (5.9%) reported PGAD.52

Although women are more commonly affected by Tarlov cysts and sexual dysfunctions, these conditions can also occur in men, although they present differently than in women.59, 60, 61 Singh et al59 reported the case of a 28-year-old man with back pain and retrograde ejaculation supposedly resulting in infertility from 2 large Tarlov cysts at the S2 to S4 sacral regions. Cysts were surgically excised, and although back pain resolved significantly after surgery, sperm count and seminal volume remained lower than the values for natural conception. In another case report,60 a 42-year-old man with symptoms of low back pain, weakness of the lower limbs, urinary incontinence, and complaints of nightly spermatorrhea (excessive involuntary seminal fluid discharge) underwent surgical removal of 2 Tarlov cysts at the S1 and S2 regions. Symptoms of spermatorrhea disappeared, and lower limb numbness and urinary incontinence improved. In addition, 2 other cases61 involved a 74-year-old man and a 38-year-old man, both with unwanted, unpleasant genital sensations and overactive bladder. In both cases, genital sensory testing indicated hyperesthesia in the pudendal dermatome, and transcutaneous electrical nerve stimulation (TENS) reduced genital sensations and overactive bowel in the 74-year-old man but had no effect in the 38-year-old man. Although small fiber sensory neuropathy was suspected in both cases, nerve conduction tests or spinal imaging was not performed.

Several investigators62, 63, 64, 65 have specifically assessed axon or nerve root injury associated with sacral Tarlov cysts. The sural nerve, composed mainly of fibers originating from the S1 and S2 sacral roots, was the target nerve. The presence and extent of nerve damage were found to be unrelated to the size of the cyst.62 Sural nerve abnormalities have been documented with smaller Tarlov cysts of <1 cm, causing nerve damage and debilitating symptoms.63 In addition, abnormal neurophysiological findings were reported in patients with Tarlov cysts referred to an American physical medicine outpatient clinic: a cohort of 30 patients and a later cohort of 31 patients.64,65 Multiple abnormal nerve conduction studies and needle EMG abnormalities in nerve root myotomes corresponded with dermatomal pain or paresthesia.63 Small fiber neuropathy evaluated with lower leg skin biopsies in patients with Tarlov cysts of ≥8 mm resulted in most biopsies being below the 5% percentile of reference values for this nerve damage.65 Small fibers are responsible for nociceptive processing, thermal sensation, and autonomic functions, and damage to these fibers may produce commonly reported Tarlov cyst–related sensory symptoms, such as burning pain, hyperesthesia, and dysesthesia. The authors proposed that the increased pulsatile CSF pressure that initiates Tarlov cyst formation, particularly in nonvalved cysts, might damage axons and neurons inside the nerve root sheaths and dorsal root ganglia.

Potential association between Tarlov cysts and persistent genital arousal disorder

Sacral Tarlov cysts are described by the ISSWSH 2019 expert consensus as a potential cause of PGAD.8 There are limited studies that directly investigate the relationships or associations between Tarlov cysts and PGAD. In Komisaruk and Lee’s66 study of an Internet-based support group for women with PGAD, sacral Tarlov cysts were present in 12 of 18 self-selected MRIs submitted. In a surgical cohort67 involving 1945 patients with cysts, 11 women were identified with PGAD symptoms and meningeal cysts, 8 of which were sacral Tarlov cysts. In a later report from the center68 of 112 women who underwent surgery for Tarlov cysts, 49.0% of women reported sexual dysfunction, and 25.5% of women reported PGAD in response to a Tarlov cyst quality-of-life questionnaire. Lim et al52 identified 2 women (5.1%) with PGAD from a cohort of 39 patients with Tarlov cysts and pudendal neuralgia referred to a pain center.

Determining whether Tarlov cysts are the cause of persistent genital arousal disorder in your patient

To determine whether a patient meets the criteria for PGAD/GPD, clinicians can use the ISSWSH 2019 consensus expert opinion.8 However, because of the multifactorial etiology of PGAD, clinicians should perform a detailed history exploring common gynecologic, medical conditions, and medication use, especially antidepressants, as PGAD has been reported after their initiation or withdrawal.26 Patients should undergo a careful gynecologic examination, as many common gynecologic conditions are potentially relevant to sexual dysfunction. Bladder dysfunctions and pelvic and genital pain frequently co-occur with PGAD, and when neuropathy is suspected, neurologic testing and/or imaging should be performed to rule out intrapelvic or spinal-related pathologies potentially causative of PGAD or associated comorbidities.

In addition, screening for Tarlov cysts involves multidisciplinary investigations. A sacral MRI is the optimal imaging technique to identify potential causes of nerve compression and confirm abnormalities in the nerve or adjacent structures, such as Tarlov cysts.6,69,70 Neurologic testing has been used to describe the locations of suspected neurologic pathology. Moreover, there are several recommended office-based somatic neurologic testing procedures71,72 for ascertaining neurologic pathology in sacral regions (Table 2). A diagnostic strategy involving the abovementioned neurologic tests has been proposed to indicate when Tarlov cysts may be involved in patient symptoms.8 In addition, the presence of symptomatic Tarlov cysts may be determined by other diagnostic tests, such as positive responses to nerve root blocks or cyst fluid aspirations, in which symptoms are significantly very much better or much better.56

Table 2.

Screening criteria for PGAD and Tarlov cysts

ISSWSH screening criteria for PGAD
1
  • Persistent or recurrent, unwanted or intrusive, distressing sensations of genital arousal.

2
  • Symptoms may include other types of genitopelvic dysesthesia (eg, buzzing, tingling, burning, twitching, itch, and pain).

3
  • Symptoms most commonly experienced in the clitoris but also in other genitopelvic regions (eg, mons pubis, vulva, vestibule, vagina, urethra, perineal region, bladder, and/or rectum).

4
  • Occurrence of symptoms can be varied from being on the verge of orgasm, experiencing uncontrollable orgasms, and/or having an excessive number of orgasms.

5
  • Symptoms are not associated with concomitant sexual interest, thoughts, or fantasies.

Office-based somatic neurologic screening tests for Tarlov cysts
1
  • The first procedure is genital quantitative sensory testing of the nerves of the clitoris, vestibule, and perianal regions(S2–S4), which consists of vibration perception threshold testing for large myelinated AB fibers and temperature perception threshold testing for small myelinated AD fibers (cold) and for unmyelinated C fibers (warm).

2 The second procedure is nongenital sacral dermatome testing in which the patient is asked to lie in the prone position, and vibration perception threshold values are obtained separately on the left and right sides in sacral innervated regions, including S1–S4 gluteal dermatomes, S1–S2 posterior thigh dermatomes, and S1–S2 posterior calf dermatomes.
3
  • The third procedure is bulbocavernosus reflex latency testing, which involves electromyographic monitoring of the bulbocavernosus muscle or external anal sphincter muscle contraction in response to mechanical stimulation of the left and right sides of the glans clitoris.

ISSWSH, International Society for the Study of Women’s Sexual Health; PGAD, persistent genital arousal disorder.

Yosef. Tarlov cysts can potentially cause persistent genital arousal disorder. Am J Obstet Gynecol Glob Rep 2025.

Treatment of persistent genital arousal disorder

The etiology of PGAD is likely multifactorial, requiring that treatment options be considered on a case-by-case basis.73 The diversity of treatments has been detailed in several systematic reviews.11,74,75 Martín-Vivar et al’s74 review of 38 studies identified 3 main treatment categories: pharmacologic therapies, physical therapies, and psychotherapeutics.

Pharmaceuticals, particularly SSRIs, were commonly reported as treatments of PGAD with mixed effectiveness, with some studies showing reductions in PGAD symptoms while other studies reporting them to be ineffective.74 In addition, treatment results with other drug classes were variable. Moreover, discontinuation of these drugs, particularly SSRIs, has been reported to be a trigger for PGAD.7,76 Psychological interventions, such as cognitive behavioral therapy and relaxation exercises, have been recommended along with medical/surgical interventions due to the psychosocial distress that patients experience with PGAD.8,73

Although a wide range of physical therapies have been reported to be effective in reducing PGAD symptoms, they have mainly involved case reports.74 Interventions include TENS,77 Botox,78, 79, 80 electroconvulsive therapy,81,82 pelvic floor therapy,83 and transcranial magnetic stimulation.84

Surgical interventions for persistent genital arousal disorder triggers

Surgical approaches targeting different potential triggers of PGAD have been used. Pelvic varices were a potential target, as an increased prevalence of pelvic varices in women with PGAD was previously reported.12 A case report85 on coil embolization involved a 64-year-old woman with symptoms of PGAD and urgency, frequency, and nocturia, diagnosed with ovarian incompetence with pelvic congestion. Treatment with percutaneous endovascular left ovarian vein coil embolization resulted in marked improvements in PGAD symptoms.

Peripheral nerve entrapments

In addition, peripheral nerve entrapments or compressions have been cited by the ISSWSH8 as a triggering factor for PGAD, depending on the nerve and region of the nerve involvement, that is, the pudendal nerve or branches or the intrapelvic portions of the sacral nerve roots. The relationship is based on the frequent association of PGAD and neurologic symptoms associated with nerve pathways that form the pudendal nerves, namely, the sacral S2, S3, and S4 nerve roots. There are many causes of pudendal nerve entrapment, including various trauma events, intrapelvic conditions, inflammatory causes, and pelvic surgeries.86 Possover et al’s87 laparoscopic investigations (n=134) for refractory anogenital pain due to suspected pudendal neuralgia revealed multiple etiologies for pudendal nerve compression, including pudendal neuralgia (n=18) and endopelvic lesions affecting the nerve root that were related either to postoperative nerve damage after pelvic surgery (n=52) or to endometriosis (n=50). Similar findings were reported by one of this article’s senior authors.14

Various surgical decompression techniques have been reported for pudendal nerve entrapment.88 Moreover, there have been multiple reports of pudendal nerve decompression for various pain-related conditions.14,87,89 Dellon et al90 after evaluating their peripheral nerve approach postulated that PGAD could be diagnosed as a compression of the dorsal branch of the pudendal nerve. Klifto and Dellon,91 following this recommendation, evaluated decompression of the dorsal branch of the pudendal nerve for 8 women with PGAD. All women reported symptom improvements, with 7 achieving complete remission with bilateral nerve decompression and 1 achieving partial remission with unilateral nerve decompression. The authors noted that 3T MRI was not helpful in documenting the nerve site of compression and that physical examination was the most helpful diagnostic technique. A genital injury was reported to be the cause of nerve compression resulting in PGAD symptoms in the women in their series.

Although PGAD was generally not reported in surgical studies for pudendal nerve entrapment, 17 of 66 women (25.8%) with pudendal neuralgia who underwent a pudendal nerve block were reported to have PGAD.92 In the cohort, previous gynecologic surgery (75.8%) and traumatic obstetrical events (47.0%) were common. In addition, multiple comorbid conditions commonly occurred, including endometriosis (21.2%), bowel disorders (31.8%), fractures (coccyx [9.1%], sacrum [3.0%], and pelvis [1.5%]), disk herniations (19.7%), and sciatica (36.4%). The results were not reported separately for the PGAD group, but most patients (92.4%) in the cohort were reported to respond positively to the pudendal nerve block. In addition, short-term improvements in PGAD symptoms were reported after pudendal nerve blockade in 2 case reports of women who had previously undergone multiple unsuccessful treatments.80,93

Neuromodulation

Neuromodulation has been recommended for failures of surgical decompression or when nerve lesions/compressions were not found87 and, depending on nerve involvement, has been performed at different sites—pudendal, sacral, and spinal. In Possover’s87 study, sacral neuromodulation with significant reductions in pain was undertaken for failed surgical decompression in 18 of 134 patients (13.4%) with pudendal pain.

Successful neuromodulation after failed pudendal nerve decompression has been reported in 3 other studies, 2 involving pudendal neuromodulation (Meier et al94 [n=15] and Gaines et al95 [n=6]) and 1 involving spinal cord stimulation (Buffenoir et al96 [n=27]). In Meier et al’s94 study, similar implantation and treatment outcomes were achieved in patients who had previously undergone unsuccessful pudendal nerve decompression (n=15) compared with those who had not had previous surgery (n=43). Although the occurrence of PGAD was not reported in these studies, 1 patient (5.3%) was reported to have PGAD in a patient cohort (n=19) with pudendal neuralgia who underwent pudendal neuromodulation.97

Several case reports of neuromodulation for patients with PGAD have been reported. Jones et al98 evaluated sacral neuromodulation for PGAD in a 32-year-old woman who experienced disturbing and PGA symptoms after antibiotic therapy for a urinary tract infection. Sacrolumbar MRI did not reveal any Tarlov cysts or nerve compression. The patient had no improvement with multiple therapies, including various medical management, pelvic floor therapy, TENS, pudendal nerve blockade, and pelvic floor Botox administration. Sacral neuromodulation with traditional device placement at the sacral S3 foramen was unsuccessful in treating an overactive bladder but was successful in reducing PGAD symptoms.

Armstrong and Vancaillie99 employed a combination of surgical (pudendal nerve release) and neuromodulation approaches to more broadly treat different pathways in a complex case. A 35-year-old woman presented with pelvic neuropathies, including PGAD, urologic dysfunctions, and gastrointestinal (GI) dysfunction. Interstitial cystitis and bilateral neuralgia resulting in pudendal nerve entrapment were potential triggers for PGAD, and a bilateral pudendal nerve release with neuromodulator implant with 2 leads at the sacral hiatus (for pelvic and perineal pain) and 2 leads adjacent to the pudendal nerves (for urinary symptoms and PGAD) was performed. Symptom improvements after the procedures were varied: a substantial reduction in urinary symptoms, mild improvements in perineal pain, and elimination of PGAD symptoms.

However, sacral neuromodulation has been associated with an unusual complication when a 57-year-old woman, after failing several pharmacologic treatments, was treated with sacral neuromodulation for urinary frequency, nocturia, and incontinence.100 Although the patient experienced marked relief in urinary symptoms, after 6 months, symptoms of PGAD and clitoral hypersensitivity emerged. Despite multiple device programming, the symptoms persisted, remained with the device turned off, and intensified when the device was turned on.

Cauda equina lumbosacral pathology

In addition, the triggers for PGAD have been suggested by the ISSWSH for those originating in the cauda equina region, including lumbar or sacral pathologies.8 Kim et al101 reported on a surgically treated subgroup of 20 patients with PGAD who had lumbosacral annular tear–induced sacral radiculopathy, selected from 168 patients with PGAD identified over a 51-month period. Abnormal findings in neurogenital testing were confirmatory for sacral radiculopathy, and annular tears were identified on sacral MRI. Before surgery, a local anesthetic administration at the site of the suspected tear, with significant reductions of PGAD/GPD (genitopelvic dysesthesia), confirmed eligibility for surgery. Lumbosacral endoscopic discectomy/annuloplasty was performed to remove fragments of trapped nucleus material, and endoscopic radiofrequency was used to ablate annular tears and fissures. Based on 3-month follow-up, 11 of 13 patients (85%) with PGAD reported overall symptom scores of “much or very much better.”

In their study, lumbosacral annular tears were commonly associated with previous injury-related events. The occurrence of PGAD after a previous injury is further substantiated in a case report of a 44-year-old woman who developed PGAD after a motor vehicle crash.102 Tarlov cysts, bony fractures, and pudendal nerve compression were not identified, but the occurrence of multilevel disk herniation and an L5/S1 radial tear and bilateral impingement on lateral recesses were likely causes of nerve compression triggering PGAD.

Treatment of Tarlov cysts

In addition, Tarlov cysts have been reported by ISSWSH to be potential triggers for PGAD.8 Although there is no consensus on patient selection or management of Tarlov cysts, there is evidence to support interventional/surgical management of Tarlov cysts in patients who have had a positive response to cyst aspiration or sacral nerve root blocks.103

Several systematic reviews104,105 have identified both percutaneous cyst aspiration and fibrin sealant and various open surgical approaches to be effective treatments of symptomatic sacral Tarlov cysts. Interventional or surgical treatment objectives for Tarlov cysts are generally to relieve nerve compression and decrease symptoms. However, it is important to highlight that all studies in the recent review of 16 surgical studies104 reported pain as the main presenting condition. Sexual dysfunction, without defined symptoms, was reported in 2 surgical studies for Tarlov cysts—4.3% (1/23)106 and 7.7% (2/13),107 although treatment effectiveness was only evaluated as pain palliation in both studies. However, sexual dysfunction, described as erectile dysfunction and loss of genital sensations, was reported as an overall postoperative complication in 27 of 333 patients (8.1%).

Treatment for patients with Tarlov cysts and outcomes on sexual dysfunction or PGAD have been reported in several other studies. In 1 study,27 women with PGAD (n=10) underwent a range of treatments, many of which providing ineffective or temporary relief (Table 1). In addition, treatments for the 5 patients with PGAD and Tarlov cysts were variable, including surgical resection of cysts with complete remission in 1 case and ineffectiveness in the other cases. In the other case, a recommendation for Tarlov cyst resection was declined, an acetazolamide trial did not improve symptoms, and immunoglobulin therapy reduced PGAD symptoms from 30 to 4 days per month.

A surgical series of women with PGAD and Tarlov cysts (n=8) causing sacral nerve root compression were treated with cyst removal, and symptoms were eliminated (n=7) or significantly better (n=3).67 In their later report,68 112 women with Tarlov cysts and 26 of 102 women (25.5%) in the cohort reporting PGAD were treated surgically for Tarlov cysts, and the prevalence of both sexual dysfunction and PGAD decreased postoperatively from 49.0% to 34.0% and from 25.5% to 17.0%, respectively.

In another surgical cohort,108 44 patients with large Tarlov cysts (at least the size of the S1 vertebral body) were treated with either partial cyst removal or cyst fenestration. Sexual dysfunctions (n=24) were commonly reported and were the primary complaint for 8 patients. All symptoms were reported to have improved within the first year. In another cohort of 213 patients with sacral Tarlov cysts treated with cyst aspiration and fibrin sealant, sexual dysfunction and bladder dysfunction were reported in 92 patients, and treatment outcomes for these symptoms were reported to be good or excellent for 74%.6

Although both percutaneous minimally invasive and surgical approaches have been effective treatments of sacral Tarlov cysts, there is no agreed-upon optimal surgical treatment.37,109,110 As the complication rate is higher and recovery is longer for surgical treatments, percutaneous interventions have been recommended as first-line treatments because of their more favorable risk-benefit profile.103

Neuromodulation

In cases where interventions for Tarlov cysts have been unsuccessful in relieving symptoms, spinal cord stimulation has been successfully employed to treat pain symptoms in 2 case reports,111,112 although neither involved PGAD. A 66-year-old woman with a history of chronic pain secondary to multiple Tarlov cysts was unsuccessfully treated with multiple medication trials, epidural steroid blocks, and superior hypogastric plexus blocks.111 After surgery to remove the cysts and sacral lamina reconstruction, the patient’s symptoms worsened. High-frequency spinal cord stimulation with device lead placements at T8 and T9 improved her pelvic pain, back pain, and radiculopathy. The second case report,112 a 45-year-old man with a history of back pain secondary to multiple Tarlov cysts, had achieved only temporary relief with multiple epidural steroid administrations and multiple cyst aspirations. A spinal cord stimulation with device lead placement at the T8 spinal level significantly reduced pain over an 8-month follow-up.

Conclusions

This narrative review provides a comprehensive overview of spontaneous PGAD, an uncommon distressing condition occurring with and without Tarlov cysts. Women with these conditions often suffer from long-standing debilitating pain and neurologic dysfunctions. Both PGAD and Tarlov cysts frequently go undetected, and when detected, they present diagnostic and therapeutic challenges requiring multidisciplinary investigations. For patients with urinary complaints or genital pain/dysesthesias, discussing sexual function is crucial due to the shared neural pathways for bladder and sexual functions.

PGAD is thought to have a multifactorial basis, and before considering treatment, detailed medical history and physical examinations are essential to evaluate relationships between symptoms, cysts, and other pathologies. In addition, the variable presentation and previous histories of women with PGAD suggest that there may be different subgroups of women with different triggers for their condition, complicating assessment, treatment approaches, and generalization of results. Pharmacologic therapies are often first-line treatments for PGAD, although results are mixed, and other physical therapies are primarily supported by case reports.

In addition to intrapelvic neuropathies, lumbosacral pathologies, including Tarlov cysts, can compress spinal and peripheral nerves, particularly the pudendal nerve and its branches, affecting urologic, GI, and sexual functions. In patients with PGAD or Tarlov cysts who have had a positive response to nerve root blocks or cyst aspiration, there is evidence supporting interventional/surgical decompression. Minimally invasive outpatient procedures, such as percutaneous cyst aspiration and fibrin administration, are recommended as first-line treatments of Tarlov cysts due to their lower complications and faster recovery compared with surgery. However, information on the success of these procedures for PGAD in women with Tarlov cysts is limited, as studies focus on pain reduction rather than PGAD specifically. For patients failing surgical interventions to decompress nerves and relieve symptoms associated with PGAD and Tarlov cysts, neuromodulation has been increasingly used as a rescue therapy.

Overall, the relationship between Tarlov cysts and PGAD remains uncertain due to the weak evidence based on many factors. The Internet-based community studies, although involving large study sizes, were dependent on self-selection and self-diagnosis and respondents reporting reliably to Internet-based questionnaires. In addition, the clinical studies tended to be smaller, without control groups, and dependent on various selection criteria, referral patterns, and methodologic expertise of the study centers. A major oversight occurs because neurosurgeons treating PGAD are generally not looking for Tarlov cysts and those treating Tarlov cysts are not looking for PGAD, as suggested by a survey of neurosurgeons57 admitting that they infrequently inquired about the sexual health of their patients. To clarify the relationship further, healthcare professionals should inquire more broadly about related symptoms, conduct relevant neurologic tests, and order sacral imaging. Given the complex interplay between neurologic, gynecologic, and urologic factors in PGAD and Tarlov cysts, increased awareness and standardized protocols for evaluating sacral pathology in patients with PGAD could improve diagnosis and guide more effective treatment strategies.

Because most current studies are observational and not well controlled, it is still unclear how Tarlov cysts and PGAD are related. To better understand this connection, future research could use designs, such as prospective cohort studies or case-control studies, to systematically evaluate women with PGAD symptoms referred to different specialty centers. These studies would aid in determining how commonly PGAD symptoms are associated with and without Tarlov cysts and whether there is a timeline that supports a stronger link. Using consistent neurologic testing, sacral imaging, and standardized symptom questionnaires would help improve diagnosis. Overall, these steps could give clearer answers about whether Tarlov cysts are a cause, a contributing factor, or just a coincidence in these cases.

CRediT authorship contribution statement

Randa Yosef: Writing – review & editing, Writing – original draft, Validation, Formal analysis, Data curation, Conceptualization. Gaylene Pron: Writing – original draft, Investigation, Formal analysis, Data curation, Conceptualization. Nucelio Lemos: Writing – review & editing, Validation, Supervision, Methodology, Investigation, Conceptualization. Kieran Murphy: Writing – review & editing, Writing – original draft, Validation, Supervision, Investigation, Data curation, Conceptualization.

Footnotes

N.L. and K.M. have equally contributed as senior authors to this work.

The authors report no conflict of interest.

Nucelio Lemos has received advisory honoraria from Integra LifeSciences and Knight Therapeutics and speaker honoraria from Medtronic and Pfizer. None of the honoraria are related to this work.

This study had no funder.

Patient consent was not required because no personal information or detail was included.

Supplementary material associated with this article can be found in the online version at doi:10.1016/j.xagr.2025.100563.

Appendix. Supplementary materials

mmc1.docx (42.5KB, docx)
mmc2.docx (48.1KB, docx)
mmc3.docx (53.8KB, docx)
mmc4.docx (46.5KB, docx)

References

  • 1.Hiers R.H., Long D., North R.B., Oaklander AL. Hiding in plain sight: a case of Tarlov perineural cysts. J Pain. 2010;11:833–837. doi: 10.1016/j.jpain.2010.07.007. [DOI] [PubMed] [Google Scholar]
  • 2.Hulens M., Rasschaert R., Bruyninckx F., et al. Symptomatic Tarlov cysts are often overlooked: ten reasons why-a narrative review. Eur Spine J. 2019;28:2237–2248. doi: 10.1007/s00586-019-05996-1. [DOI] [PubMed] [Google Scholar]
  • 3.Murphy K.J., Nussbaum D.A., Schnupp S., Long D. Tarlov cysts: an overlooked clinical problem. Semin Musculoskelet Radiol. 2011;15:163–167. doi: 10.1055/s-0031-1275599. [DOI] [PubMed] [Google Scholar]
  • 4.Baker M., Wilson M., Wallach S. Urogenital symptoms in women with Tarlov cysts. J Obstet Gynaecol Res. 2018;44:1817–1823. doi: 10.1111/jog.13711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Hulens M.A., Dankaerts W., Rasschaert R., et al. Can patients with symptomatic Tarlov cysts be differentiated from patients with specific low back pain based on comprehensive history taking? Acta Neurochir. 2018;160:839–844. doi: 10.1007/s00701-018-3494-z. [DOI] [PubMed] [Google Scholar]
  • 6.Murphy K., Oaklander A.L., Elias G., Kathuria S., Long DM. Treatment of 213 patients with symptomatic Tarlov cysts by CT-guided percutaneous injection of fibrin sealant. AJNR Am J Neuroradiol. 2016;37:373–379. doi: 10.3174/ajnr.A4517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Facelle T.M., Sadeghi-Nejad H., Goldmeier D. Persistent genital arousal disorder: characterization, etiology, and management. J Sex Med. 2013;10:439–450. doi: 10.1111/j.1743-6109.2012.02990.x. [DOI] [PubMed] [Google Scholar]
  • 8.Goldstein I., Komisaruk B.R., Pukall C.F., et al. International Society for the Study of Women’s Sexual Health (ISSWSH) Review of Epidemiology and Pathophysiology, and a consensus nomenclature and process of care for the management of persistent genital arousal disorder/genito-pelvic dysesthesia (PGAD/GPD) J Sex Med. 2021;18:665–697. doi: 10.1016/j.jsxm.2021.01.172. [DOI] [PubMed] [Google Scholar]
  • 9.Jackowich R.A., Pink L., Gordon A., Pukall CF. Persistent genital arousal disorder: a review of Its conceptualizations, potential origins, impact, and treatment. Sex Med Rev. 2016;4:329–342. doi: 10.1016/j.sxmr.2016.06.003. [DOI] [PubMed] [Google Scholar]
  • 10.Pukall C.F., Jackowich R., Mooney K., Chamberlain SM. Genital sensations in persistent genital arousal disorder: a case for an overarching nosology of genitopelvic dysesthesias? Sex Med Rev. 2019;7:2–12. doi: 10.1016/j.sxmr.2018.08.001. [DOI] [PubMed] [Google Scholar]
  • 11.Pease E.R., Ziegelmann M., Vencill J.A., Kok S.N., Collins C.S., Betcher HK. Persistent genital arousal disorder (PGAD): a clinical review and case series in support of multidisciplinary management. Sex Med Rev. 2022;10:53–70. doi: 10.1016/j.sxmr.2021.05.001. [DOI] [PubMed] [Google Scholar]
  • 12.Waldinger M.D., van Gils A.P., Ottervanger H.P., Vandenbroucke W.V.A., Tavy DLJ. Persistent genital arousal disorder in 18 Dutch women: Part I. MRI, EEG, and transvaginal ultrasonography investigations. J Sex Med. 2009;6:474–481. doi: 10.1111/j.1743-6109.2008.01113.x. [DOI] [PubMed] [Google Scholar]
  • 13.Klifto K.M., Dellon AL. Persistent genital arousal disorder: review of pertinent peripheral nerves. Sex Med Rev. 2020;8:265–273. doi: 10.1016/j.sxmr.2019.10.001. [DOI] [PubMed] [Google Scholar]
  • 14.Lemos N., Sermer C., Fernandes G., et al. Laparoscopic approach to refractory extraspinal sciatica and pudendal pain caused by intrapelvic nerve entrapment. Sci Rep. 2021;11 doi: 10.1038/s41598-021-90319-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Moscicki P., Bachmann GA. Characterization of female sexual dysfunction associated with spinal pathology and surgery. Sex Med Rev. 2022;10:493–498. doi: 10.1016/j.sxmr.2022.01.003. [DOI] [PubMed] [Google Scholar]
  • 16.Leiblum S.R., Nathan SG. Persistent sexual arousal syndrome: a newly discovered pattern of female sexuality. J Sex Marital Ther. 2001;27:365–380. doi: 10.1080/009262301317081115. [DOI] [PubMed] [Google Scholar]
  • 17.Jackowich R.A., Pukall CF. Prevalence of persistent genital arousal disorder in 2 North American samples. J Sex Med. 2020;17:2408–2416. doi: 10.1016/j.jsxm.2020.09.004. [DOI] [PubMed] [Google Scholar]
  • 18.Dèttore D., Pagnini G. Persistent genital arousal disorder: a study on an Italian group of female university students. J Sex Marital Ther. 2021;47:60–79. doi: 10.1080/0092623X.2020.1804022. [DOI] [PubMed] [Google Scholar]
  • 19.Jackowich R., Pink L., Gordon A., Poirier É, Pukall CF. Symptom characteristics and medical history of an online sample of women experience symptoms of persistent genital arousal. J Sex Marital Ther. 2018;44:111–126. doi: 10.1080/0092623X.2017.1321598. [DOI] [PubMed] [Google Scholar]
  • 20.Leiblum S., Brown C., Wan J., Rawlinson L. Persistent sexual arousal syndrome: a descriptive study. J Sex Med. 2005;2:331–337. doi: 10.1111/j.1743-6109.2005.20357.x. [DOI] [PubMed] [Google Scholar]
  • 21.Leiblum S., Seehuus M., Brown C. Persistent genital arousal: disordered or normative aspect of female sexual response? J Sex Med. 2007;4:680–689. doi: 10.1111/j.1743-6109.2007.00495.x. [DOI] [PubMed] [Google Scholar]
  • 22.Jackowich R.A., Pink L., Gordon A., Poirier É, Pukall CF. An online cross-sectional comparison of women with symptoms of persistent genital arousal, painful persistent genital arousal, and chronic vulvar pain. J Sex Med. 2018;15:558–567. doi: 10.1016/j.jsxm.2018.02.007. [DOI] [PubMed] [Google Scholar]
  • 23.Jackowich R.A., Poirier É, Pukall CF. A comparison of medical comorbidities, psychosocial, and sexual well-being in an online cross-sectionsl sample of women experiencing persistent genital arousal symptoms and a control group. J Sex Med. 2020;17:69–82. doi: 10.1016/j.jsxm.2019.09.016. [DOI] [PubMed] [Google Scholar]
  • 24.Kümpers FMLM, Sinke C., Schippert C., et al. Clinical characterisation of women with persistent genital arousal disorder: the iPGAD-study. Sci Rep. 2023;13 doi: 10.1038/s41598-023-48790-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Garvey L.J., West C., Latch N., Leiblum S., Goldmeier D. Report of spontaneous and persistent genital arousal in women attending a sexual health clinic. Int J STD AIDS. 2009;20:519–521. doi: 10.1258/ijsa.2008.008492. [DOI] [PubMed] [Google Scholar]
  • 26.Pink L., Rancourt V., Gordon A. Persistent genital arousal in women with pelvic and genital pain. J Obstet Gynaecol Can. 2014;36:324–330. doi: 10.1016/S1701-2163(15)30608-3. [DOI] [PubMed] [Google Scholar]
  • 27.Oaklander A.L., Sharma S., Kessler K., Price BH. Persistent genital arousal disorder: a special sense neuropathy. Pain Rep. 2020;5:e801. doi: 10.1097/PR9.0000000000000801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Waldinger M.D., Schweitzer DH. Persistent genital arousal disorder in 18 Dutch women: Part II. A syndrome clustered with restless legs and overactive bladder. J Sex Med. 2009;6:482–497. doi: 10.1111/j.1743-6109.2008.01114.x. [DOI] [PubMed] [Google Scholar]
  • 29.Villot A., Thubert T., Deffieux X., et al. Perineal neurophysiological assessment in 23 patients suffering from persistent genital arousal disorders: evidence of pudendal neuropathy? Int J Sex Health. 2016;28:50–54. [Google Scholar]
  • 30.Konar S.K., Bir S.C., Maiti T.K., Bollam P., Nanda A., Tarlov I.M. (1905-1977) and the controversial Tarlov cyst: historical perspective. J Neurosurg Spine. 2016;24:510–513. doi: 10.3171/2015.5.SPINE1590. [DOI] [PubMed] [Google Scholar]
  • 31.Paulsen R.D., Call G.A., Murtagh FR. Prevalence and percutaneous drainage of cysts of the sacral nerve root sheath (Tarlov cysts) AJNR Am J Neuroradiol. 1994;15:293–297. discussion 8–9. [PMC free article] [PubMed] [Google Scholar]
  • 32.Nishiura I., Koyama T., Handa J. Intrasacral perineurial cyst. Surg Neurol. 1985;23:265–269. doi: 10.1016/0090-3019(85)90093-x. [DOI] [PubMed] [Google Scholar]
  • 33.Voyadzis J.M., Bhargava P., Henderson FC. Tarlov cysts: a study of 10 cases with review of the literature. J Neurosurg. 2001;95(Suppl):25–32. doi: 10.3171/spi.2001.95.1.0025. [DOI] [PubMed] [Google Scholar]
  • 34.Tarlov IM. Cysts of the sacral nerve roots; clinical significance and pathogenesis. AMA Arch Neurol Psychiatry. 1952;68:94–108. doi: 10.1001/archneurpsyc.1952.02320190100010. [DOI] [PubMed] [Google Scholar]
  • 35.Akahori S., Nishimura Y., Eguchi K., et al. Spontaneous rupture of a huge presacral cyst leading to dramatic neurologic recovery. World Neurosurg. 2021;145:306–310. doi: 10.1016/j.wneu.2020.09.098. [DOI] [PubMed] [Google Scholar]
  • 36.Guo D., Shu K., Chen R., Ke C., Zhu Y., Lei T. Microsurgical treatment of symptomatic sacral perineurial cysts. Neurosurgery. 2007;60:1059–1066. doi: 10.1227/01.NEU.0000255457.12978.78. [DOI] [PubMed] [Google Scholar]
  • 37.Tanaka M., Nakahara S., Ito Y., et al. Surgical results of sacral perineural (Tarlov) cysts. Acta Med Okayama. 2006;60:65–70. doi: 10.18926/AMO/30758. [DOI] [PubMed] [Google Scholar]
  • 38.Arnold P.M., Teuber J. Marfan syndrome and symptomatic sacral cyst: report of two cases. J Spinal Cord Med. 2013;36:499–503. doi: 10.1179/2045772312Y.0000000079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Pyeritz R.E., Fishman E.K., Bernhardt B.A., Siegelman SS. Dural ectasia is a common feature of the Marfan syndrome. Am J Hum Genet. 1988;43:726–732. [PMC free article] [PubMed] [Google Scholar]
  • 40.Isono M., Hori S., Konishi Y., et al. Ehlers-Danlos syndrome associated with multiple spinal meningeal cysts—case report. Neurol Med Chir (Tokyo) 1999;39:380–383. doi: 10.2176/nmc.39.380. [DOI] [PubMed] [Google Scholar]
  • 41.Paterakis K., Brotis A., Bakopoulou M., et al. A giant Tarlov cyst presenting with hydronephrosis in a patient with Marfan syndrome: a case report and review of the literature. World Neurosurg. 2019;126:581–587. doi: 10.1016/j.wneu.2019.02.222. [DOI] [PubMed] [Google Scholar]
  • 42.Burdan F., Mocarska A., Janczarek M., et al. Incidence of spinal perineurial (Tarlov) cysts among East-European patients. PLoS One. 2013;8 doi: 10.1371/journal.pone.0071514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Joo J., Kim J., Lee J. The prevalence of anatomical variations that can cause inadvertent dural puncture when performing caudal block in Koreans: a study using magnetic resonance imaging. Anaesthesia. 2010;65:23–26. doi: 10.1111/j.1365-2044.2009.06168.x. [DOI] [PubMed] [Google Scholar]
  • 44.Kozłowski P., Kalinowski P., Kozłowska M., et al. Spinal perineural cysts among European patients. J Neurol Surg A Cent Eur Neurosurg. 2021;82:463–467. doi: 10.1055/s-0040-1722194. [DOI] [PubMed] [Google Scholar]
  • 45.Kuhn F.P., Hammoud S., Lefèvre-Colau M.M., Poiraudeau S., Feydy A. Prevalence of simple and complex sacral perineural Tarlov cysts in a French cohort of adults and children. J Neuroradiol. 2017;44:38–43. doi: 10.1016/j.neurad.2016.09.006. [DOI] [PubMed] [Google Scholar]
  • 46.Langdown A.J., Grundy J.R.B., Birch NC. The clinical relevance of Tarlov cysts. J Spinal Disord Tech. 2005;18:29–33. doi: 10.1097/01.bsd.0000133495.78245.71. [DOI] [PubMed] [Google Scholar]
  • 47.Park H.J., Jeon Y.H., Rho M.H., et al. Incidental findings of the lumbar spine at MRI during herniated intervertebral disk disease evaluation. AJR Am J Roentgenol. 2011;196:1151–1155. doi: 10.2214/AJR.10.5457. [DOI] [PubMed] [Google Scholar]
  • 48.Senoglu N., Senoglu M., Ozkan F., Kesilmez C., Kızıldag B., Celik M. The level of termination of the dural sac by MRI and its clinical relevance in caudal epidural block in adults. Surg Radiol Anat. 2013;35:579–584. doi: 10.1007/s00276-013-1108-2. [DOI] [PubMed] [Google Scholar]
  • 49.Shoyab M. Tarlov cysts in back pain patients: prevalence, measurement method and reporting points. Br J Radiol. 2021;94 doi: 10.1259/bjr.20210505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Klepinowski T., Orbik W., Sagan L. Global incidence of spinal perineural Tarlov’s cysts and their morphological characteristics: a meta-analysis of 13,266 subjects. Surg Radiol Anat. 2021;43:855–863. doi: 10.1007/s00276-020-02644-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Hulens M., Bruyninckx F., Dankaerts W., et al. High prevalence of perineural cysts in patients with fibromyalgia and chronic fatigue syndrome. Pain Med. 2021;22:883–890. doi: 10.1093/pm/pnaa410. [DOI] [PubMed] [Google Scholar]
  • 52.Lim V.M., Khanna R., Kalinkin O., Castellanos M.E., Hibner M. Evaluating the discordant relationship between Tarlov cysts and symptoms of pudendal neuralgia. Am J Obstet Gynecol. 2020;222:70.e1–70.e6. doi: 10.1016/j.ajog.2019.07.021. [DOI] [PubMed] [Google Scholar]
  • 53.Tani S., Hata Y., Tochigi S., et al. Prevalence of spinal meningeal cyst in the sacrum. Neurol Med Chir (Tokyo) 2013;53:91–94. doi: 10.2176/nmc.53.91. [DOI] [PubMed] [Google Scholar]
  • 54.Kassem H., Urits I., Hasoon J., Kaye A.D., Viswanath O. Tarlov cysts in a 49-year-old woman presenting with bilateral lower-extremity radiculopathy: A case report. Case Rep Womens Health. 2020;28 doi: 10.1016/j.crwh.2020.e00248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Nadler S.F., Bartoli L.M., Stitik T.P., Chen B. Tarlov cyst as a rare cause of S1 radiculopathy: A case report. Arch Phys Med Rehabil. 2001;82:689–690. doi: 10.1053/apmr.2001.22353. [DOI] [PubMed] [Google Scholar]
  • 56.Murphy K.P., Ryan S. Shrinking of a Tarlov cyst. BMJ Case Rep. 2019;12 doi: 10.1136/bcr-2018-227256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Korse N.S., Nicolai M.P., Both S., Vleggeert-Lankamp C.L., Elzevier HW. Discussing sexual health in spinal care. Eur Spine J. 2016;25:766–773. doi: 10.1007/s00586-015-3991-1. [DOI] [PubMed] [Google Scholar]
  • 58.Marino D., Carluccio M.A., Di Donato I., et al. Tarlov cysts: clinical evaluation of an Italian cohort of patients. Neurol Sci. 2013;34:1679–1682. doi: 10.1007/s10072-013-1321-0. [DOI] [PubMed] [Google Scholar]
  • 59.Singh P.K., Singh V.K., Azam A., Gupta S. Tarlov cyst and infertility. J Spinal Cord Med. 2009;32:191–197. doi: 10.1080/10790268.2009.11760771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Sun P., Xu W., Ye Y., Zhong F., Wan X., Li Y. Neglected Tarlov cysts: a case of a Tarlov cyst with spermatorrhea. Eur J Med Res. 2021;26:44. doi: 10.1186/s40001-021-00514-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Waldinger M.D., Venema P.L., van Gils A.P., de Lint G.J., Schweitzer DH. Stronger evidence for small fiber sensory neuropathy in restless genital syndrome: two case reports in males. J Sex Med. 2011;8:325–330. doi: 10.1111/j.1743-6109.2010.02079.x. [DOI] [PubMed] [Google Scholar]
  • 62.Cattaneo L., Pavesi G., Mancia D. Sural nerve abnormalities in sacral perineural (Tarlov) cysts. J Neurol. 2001;248:623–624. doi: 10.1007/s004150170144. [DOI] [PubMed] [Google Scholar]
  • 63.Hulens M., Bruyninckx F., Dankaerts W., Vansant G., De Mulder PA. Electromyographic abnormalities associated with symptomatic sacral Tarlov cysts. Pain Pract. 2016;16:E81–E88. doi: 10.1111/papr.12441. [DOI] [PubMed] [Google Scholar]
  • 64.Mieke H., Frans B., Alix S., et al. Electromyography and a review of the literature provide insights into the role of sacral perineural cysts in unexplained chronic pelvic, perineal and leg pain syndromes. Int J Phys Med Rehabil. 2017;5:3. doi: 10.4172/2329-9096.1000407. [DOI] [Google Scholar]
  • 65.Hulens M., Bruyninckx F., Thal D.R., Rasschaert R., Bervoets C., Dankaerts W. Large- and small-fiber neuropathy in patients with Tarlov cysts. J Pain Res. 2022;15:193–202. doi: 10.2147/JPR.S342759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Komisaruk B.R., Lee HJ. Prevalence of sacral spinal (Tarlov) cysts in persistent genital arousal disorder. J Sex Med. 2012;9:2047–2056. doi: 10.1111/j.1743-6109.2012.02765.x. [DOI] [PubMed] [Google Scholar]
  • 67.Feigenbaum F., Boone K. Persistent genital arousal disorder caused by spinal meningeal cysts in the sacrum: successful neurosurgical treatment. Obstet Gynecol. 2015;126:839–843. doi: 10.1097/AOG.0000000000001060. [DOI] [PubMed] [Google Scholar]
  • 68.Feigenbaum F., Parks S.E., Chapple KM. Prospective validation of a quality-of-life measure for women undergoing surgical intervention for symptomatic sacral Tarlov cysts: the Tarlov cyst quality of life scale. World Neurosurg. 2022;165:e276–e281. doi: 10.1016/j.wneu.2022.06.033. [DOI] [PubMed] [Google Scholar]
  • 69.Boukobza M., Roussel A., Fernandez-Rodriguez P., Laissy JP. Giant multiple and bilateral presacral Tarlov cysts mimicking adnexal mass—imaging features. Int Med Case Rep J. 2018;11:181–184. doi: 10.2147/IMCRJ.S147791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Vargas M.I., Delattre B.M.A., Boto J., et al. Advanced magnetic resonance imaging (MRI) techniques of the spine and spinal cord in children and adults. Insights Imaging. 2018;9:549–557. doi: 10.1007/s13244-018-0626-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Burke Y.Z., Lowenstein L. Value of quantitative sensory testing in the evaluation of genital sensation: its application to female sexual dysfunction. Sex Med Rev. 2016;4:121–125. doi: 10.1016/j.sxmr.2015.10.009. [DOI] [PubMed] [Google Scholar]
  • 72.Wester C., FitzGerald M.P., Brubaker L., Welgoss J., Benson JT. Validation of the clinical bulbocavernosus reflex. Neurourol Urodyn. 2003;22:589–592. doi: 10.1002/nau.10140. [DOI] [PubMed] [Google Scholar]
  • 73.Jackowich R.A., Pukall CF. Persistent genital arousal disorder: a biopsychosocial framework. Curr Sex Health Rep. 2020;12:127–135. [Google Scholar]
  • 74.Martín-Vivar M., Villena-Moya A., Mestre-Bach G., Hurtado-Murillo F., Chiclana-Actis C. Treatments for persistent genital arousal disorder in women: a scoping review. J Sex Med. 2022;19:961–974. doi: 10.1016/j.jsxm.2022.03.220. [DOI] [PubMed] [Google Scholar]
  • 75.Mulroy M.E., Pukall CF. Persistent genital arousal disorder/genitopelvic dysesthesia:review of the current state of the treatment literature and future directions in treatment. Curr Sex Health Rep. 2023;15:231–243. doi: 10.1007/s11930-023-00366-x. [DOI] [Google Scholar]
  • 76.Kruger THC. Can pharmacotherapy help persistent genital arousal disorder? Expert Opin Pharmacother. 2018;19:1705–1709. doi: 10.1080/14656566.2018.1525359. [DOI] [PubMed] [Google Scholar]
  • 77.Waldinger M.D., de Lint G.J., Venema P.L., van Gils A.P., Schweitzer DH. Successful transcutaneous electrical nerve stimulation in two women with restless genital syndrome: the role of adelta- and C-nerve fibers. J Sex Med. 2010;7:1190–1199. doi: 10.1111/j.1743-6109.2009.01578.x. [DOI] [PubMed] [Google Scholar]
  • 78.Dick B., Natale C., Reddy A., Akula K.P., Yousif A., Hellstrom WJG. Application of botulinum neurotoxin in female sexual and genitourinary dysfunction: a review of current practices. Sex Med Rev. 2021;9:57–63. doi: 10.1016/j.sxmr.2020.01.003. [DOI] [PubMed] [Google Scholar]
  • 79.Nazik H., Api M., Aytan H., Narin R. A new medical treatment with botulinum toxin in persistent genital arousal disorder: successful treatment of two cases. J Sex Marital Ther. 2014;40:170–174. doi: 10.1080/0092623X.2013.788109. [DOI] [PubMed] [Google Scholar]
  • 80.Cohen SD. Diagnosis and treatment of persistent genital arousal disorder. Rev Urol. 2017;19:265–267. doi: 10.3909/riu0784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Korda J.B., Pfaus J.G., Kellner C.H., Goldstein I. Persistent genital arousal disorder (PGAD): case report of long-term symptomatic management with electroconvulsive therapy. J Sex Med. 2009;6:2901–2909. doi: 10.1111/j.1743-6109.2009.01421.x. [DOI] [PubMed] [Google Scholar]
  • 82.Yero S.A., McKinney T., Petrides G., Goldstein I., Kellner CH. Successful use of electroconvulsive therapy in 2 cases of persistent sexual arousal syndrome and bipolar disorder. J ECT. 2006;22:274–275. doi: 10.1097/01.yct.0000244247.33038.26. [DOI] [PubMed] [Google Scholar]
  • 83.Rosenbaum TY. Physical therapy treatment of persistent genital arousal disorder during pregnancy: a case report. J Sex Med. 2010;7:1306–1310. doi: 10.1111/j.1743-6109.2009.01654.x. [DOI] [PubMed] [Google Scholar]
  • 84.McMullen R., Agarwal S. Persistent genital arousal disorder-case report of symptomatic relief of symptoms with transcranial magnetic stimulation. J ECT. 2016;32:e9–e10. doi: 10.1097/YCT.0000000000000299. [DOI] [PubMed] [Google Scholar]
  • 85.Thorne C., Stuckey B. Pelvic congestion syndrome presenting as persistent genital arousal: a case report. J Sex Med. 2008;5:504–508. doi: 10.1111/j.1743-6109.2007.00666.x. [DOI] [PubMed] [Google Scholar]
  • 86.Aoun F., Alkassis M., Tayeh G.A., et al. Sexual dysfunction due to pudendal neuralgia: a systematic review. Transl Androl Urol. 2021;10:2500–2511. doi: 10.21037/tau-21-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Possover M. Laparoscopic management of endopelvic etiologies of pudendal pain in 134 consecutive patients. J Urol. 2009;181:1732–1736. doi: 10.1016/j.juro.2008.11.096. [DOI] [PubMed] [Google Scholar]
  • 88.Mylle T., De Corte R., Hervé F., Everaert K., Bou Kheir G. Surgical approaches for pudendal nerve entrapment: insights from a systematic review and meta-analysis. Surg Endosc. 2024;38:4160–4170. doi: 10.1007/s00464-024-10990-w. [DOI] [PubMed] [Google Scholar]
  • 89.Bollens R., Mjaess G., Sarkis J., et al. Laparoscopic transperitoneal pudendal nerve and artery release for pudendal entrapment syndrome. Surg Endosc. 2021;35:6031–6038. doi: 10.1007/s00464-020-08092-4. [DOI] [PubMed] [Google Scholar]
  • 90.Dellon A.L., Coady D., Harris D. Pelvic pain of pudendal nerve origin: surgical outcomes and learning curve lessons. J Reconstr Microsurg. 2015;31:283–290. doi: 10.1055/s-0034-1396896. [DOI] [PubMed] [Google Scholar]
  • 91.Klifto K., Dellon AL. Persistent genital arousal disorder: treatment by neurolysis of dorsal branch of pudendal nerve. Microsurgery. 2020;40:160–166. doi: 10.1002/micr.30464. [DOI] [PubMed] [Google Scholar]
  • 92.Vancaillie T., Eggermont J., Armstrong G., Jarvis S., Liu J., Beg N. Response to pudendal nerve block in women with pudendal neuralgia. Pain Med. 2012;13:596–603. doi: 10.1111/j.1526-4637.2012.01343.x. [DOI] [PubMed] [Google Scholar]
  • 93.Gyorfi M.J., Abd-Elsayed A. Pudendal nerve blockade for persistent genital arousal disorder (PGAD): A clinical review and case report. Pain Pract. 2024;24:852–855. doi: 10.1111/papr.13362. [DOI] [PubMed] [Google Scholar]
  • 94.Meier K.M., Vecellio P.M., Killinger K.A., Boura J.A., Peters KM. Pudendal neuromodulation is feasible and effective after pudendal nerve entrapment surgery. J Sex Med. 2022;19:995–1001. doi: 10.1016/j.jsxm.2022.03.219. [DOI] [PubMed] [Google Scholar]
  • 95.Gaines N., Odom B.D., Killinger K.A., Peters KM. Pudendal neuromodulation as a treatment for persistent genital arousal disorder-a case series. Female Pelvic Med Reconstr Surg. 2018;24:e1–e5. doi: 10.1097/SPV.0000000000000435. [DOI] [PubMed] [Google Scholar]
  • 96.Buffenoir K., Rioult B., Hamel O., Labat J.J., Riant T., Robert R. Spinal cord stimulation of the conus medullaris for refractory pudendal neuralgia: a prospective study of 27 consecutive cases. Neurourol Urodyn. 2015;34:177–182. doi: 10.1002/nau.22525. [DOI] [PubMed] [Google Scholar]
  • 97.Peters K.M., Killinger K.A., Jaeger C., Chen C. Pilot study exploring chronic pudendal neuromodulation as a treatment option for pain associated with pudendal neuralgia. Low Urin Tract Symptoms. 2015;7:138–142. doi: 10.1111/luts.12066. [DOI] [PubMed] [Google Scholar]
  • 98.Jones C.L., Fischer J.R., Hernandez SL. Sacral neuromodulation for the treatment of persistent genital arousal disorder. Obstet Gynecol. 2016;128:321–323. doi: 10.1097/AOG.0000000000001452. [DOI] [PubMed] [Google Scholar]
  • 99.Armstrong G.L., Vancaillie TG. Combined site-specific sacral neuromodulation and pudendal nerve release surgery in a patient with interstitial cystitis and persistent arousal. BMJ Case Rep. 2016 doi: 10.1136/bcr-2015-213513. 2016:bcr2015213513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Zoorob D., Deis A.S., Lindsay K. Refractory sexual arousal subsequent to sacral neuromodulation. Case Rep Obstet Gynecol. 2019;2019 doi: 10.1155/2019/7519164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Kim C.W., Goldstein I., Komisaruk B.R., et al. Lumbar endoscopic spine surgery for persistent genital arousal disorder/genitopelvic dysesthesia resulting from lumbosacral annular tear-induced sacral radiculopathy. J Sex Med. 2023;20:210–223. doi: 10.1093/jsxmed/qdac017. [DOI] [PubMed] [Google Scholar]
  • 102.Parus A., Kanhai M., Tramont JM. Persistent genital arousal disorder after motor vehicle accident: a case report. Womens Health Rep (New Rochelle) 2020;1:341–344. doi: 10.1089/whr.2020.0043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Murphy K., Nasralla M., Pron G., Almohaimede K., Schievink W. Management of Tarlov cysts: an uncommon but potentially serious spinal column disease-review of the literature and experience with over 1000 referrals. Neuroradiology. 2024;66:1–30. doi: 10.1007/s00234-023-3226-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Kameda-Smith M.M., Fathalla Z., Ibrahim N., Astaneh B., Farrokhyar F. A systematic review of the efficacy of surgical intervention in the management of symptomatic Tarlov cysts: a meta-analysis. Br J Neurosurg. 2024;38:49–60. doi: 10.1080/02688697.2021.1874294. [DOI] [PubMed] [Google Scholar]
  • 105.Sharma M., SirDeshpande P., Ugiliweneza B., Dietz N., Boakye M. A systematic comparative outcome analysis of surgical versus percutaneous techniques in the management of symptomatic sacral perineural (Tarlov) cysts: a meta-analysis. J Neurosurg Spine. 2019;30:623–634. doi: 10.3171/2018.10.SPINE18952. [DOI] [PubMed] [Google Scholar]
  • 106.Burke J.F., Thawani J.P., Berger I., et al. Microsurgical treatment of sacral perineural (Tarlov) cysts: case series and review of the literature. J Neurosurg Spine. 2016;24:700–707. doi: 10.3171/2015.9.SPINE153. [DOI] [PubMed] [Google Scholar]
  • 107.Weigel R., Polemikos M., Uksul N., Krauss JK. Tarlov cysts: long-term follow-up after microsurgical inverted plication and sacroplasty. Eur Spine J. 2016;25:3403–3410. doi: 10.1007/s00586-016-4744-5. [DOI] [PubMed] [Google Scholar]
  • 108.Galarza M., Chaban G., Gazzeri R., et al. Functional recovery following resection of large Tarlov cyst malformation: a multicentre longitudinal cohort study. Acta Neurochir (Wien) 2021;163:2769–2776. doi: 10.1007/s00701-021-04817-z. [DOI] [PubMed] [Google Scholar]
  • 109.Elsawaf A., Awad T.E. Fesal SS. Surgical excision of symptomatic sacral perineurial Tarlov cyst: case series and review of the literature. Eur Spine J. 2016;25:3385–3392. doi: 10.1007/s00586-016-4584-3. [DOI] [PubMed] [Google Scholar]
  • 110.Tsitsopoulos P.P., Marklund N., Salci K., Holtz A., Mani M. Management of symptomatic sacral perineural cysts with microsurgery and a vascularized fasciocutaneous flap. J Spine Surg. 2018;4:602–609. doi: 10.21037/jss.2018.07.02. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Hasoon J., Berger A.A., Urits I., Orhurhu V., Viswanath O., Aner M. Spinal cord stimulation for the treatment of chronic pelvic pain after Tarlov cyst surgery in a 66-year-old woman: a case report. Case Rep Womens Health. 2020;25 doi: 10.1016/j.crwh.2020.e00171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112.On J., Polania Gutierrez J.J., Plaza-Lloret M., Dua A., Sun Z. Spinal cord stimulation for the treatment of refractory pain from Tarlov cysts: a case report. Cureus. 2023;15 doi: 10.7759/cureus.33928. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

mmc1.docx (42.5KB, docx)
mmc2.docx (48.1KB, docx)
mmc3.docx (53.8KB, docx)
mmc4.docx (46.5KB, docx)

Articles from AJOG Global Reports are provided here courtesy of Elsevier

RESOURCES